Shamburg News · 8-K filed Nov 10, 2026, 8:06 AM EST

TriSalus Life Sciences Reports Q3 2026 Revenue of $12.9 Million and Revises 2026 Guidance

TLSI · TriSalus Life Sciences, Inc.

  • Earnings
  • Materiality: high

On November 10, 2026, TriSalus Life Sciences reported third quarter 2026 revenue of $12.9 million, up 11.3% year over year, and a net loss attributable to common stockholders of $8.9 million, or $0.15 per share. The company updated its full-year 2026 revenue guidance to $46 million to $48 million. Adjusted EBITDA losses were $4.7 million for the quarter, compared with $5.4 million a year earlier.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001628280-26-072513.

Written from the filing by Shamburg Markets. Figures are as reported by the company.